Clinical Cancer Drugs - Volume 7, Issue 1, 2020

More than 90% of new potential therapeutic drugs have failed in clinical trials. In this study, the characteristics of failed new drugs for the treatment of seven types of cancer were first examined, followed by a review of the hazard ratios of survival in typical phase III clinical drug trials of these cancers from the last five years. The data suggested that population sizes in most clinical trials were limited to a certain level of Read More

Background: Larynx cancer (LCa) is the most common head and neck cancer and accounts for 1-2.5% of all human cancers worldwide. Metformin, an oral anti-diabetic drug, has been recently shown to have anti-cancer activity in various cancer types, and there are several studies in the literature pointing to its potential to sensitize cancer cells to chemotherapeutic drugs. Objective: This study was aimed at exploring the a Read More

Background: Breast Cancer is a recurrent problem across the world. According to a report, breast cancer has the second highest mortality rate in women globally. Despite having an advanced degree of chemotherapy, resistance is developed against the therapies. Studies showed that anthracyclins like doxorubicin used in the treatment of breast cancer are found to develop resistance, which is not easy to identify. Muta Read More

Background: Recent human and animal studies have demonstrated the oncostatic properties of N-acetyl-5-methoxytryptamine (melatonin) in different types of cancer. However, in few cancer cell lines including colorectal cancer cell line (HT-29), acute T cell leukemia cell line (JURKAT) and cervical cancer cell line (HeLa), precise oncostatic mechanism induced by melatonin is yet to be described. Objectives: The aim of this st Read More

Background: Gefitinib was approved by the Food and Drug Administration (FDA) of the United States (US) for the treatment of advanced non-small cell carcinoma harboring sensitizing epidermal growth factor receptor (EGFR) mutations. The use of gastric acid-suppressing medication inhibits gefitinib absorption and reduces its plasma concentration, but retrospective studies on whether there is the corresponding repercussion Read More